181 related articles for article (PubMed ID: 32200025)
1. Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy.
Nguyen KM; Busino L
Semin Cancer Biol; 2020 Dec; 67(Pt 2):53-60. PubMed ID: 32200025
[TBL] [Abstract][Full Text] [Related]
2. A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.
Yamanaka S; Horiuchi Y; Matsuoka S; Kido K; Nishino K; Maeno M; Shibata N; Kosako H; Sawasaki T
Nat Commun; 2022 Jan; 13(1):183. PubMed ID: 35013300
[TBL] [Abstract][Full Text] [Related]
3. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.
Ito T; Handa H
Int J Hematol; 2016 Sep; 104(3):293-9. PubMed ID: 27460676
[TBL] [Abstract][Full Text] [Related]
4. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
Ito T; Yamaguchi Y; Handa H
Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
[TBL] [Abstract][Full Text] [Related]
5. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.
Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK
J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372
[TBL] [Abstract][Full Text] [Related]
6. Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs.
Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB
Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.
Li D; Yu X; Kottur J; Gong W; Zhang Z; Storey AJ; Tsai YH; Uryu H; Shen Y; Byrum SD; Edmondson RD; Mackintosh SG; Cai L; Liu Z; Aggarwal AK; Tackett AJ; Liu J; Jin J; Wang GG
Oncogene; 2022 Jun; 41(24):3328-3340. PubMed ID: 35525905
[TBL] [Abstract][Full Text] [Related]
8. Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera.
Kim K; Lee DH; Park S; Jo SH; Ku B; Park SG; Park BC; Jeon YU; Ahn S; Kang CH; Hwang D; Chae S; Ha JD; Kim S; Hwang JY; Kim JH
Sci Rep; 2019 Dec; 9(1):19654. PubMed ID: 31873151
[TBL] [Abstract][Full Text] [Related]
9. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
10. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
[TBL] [Abstract][Full Text] [Related]
11. pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate.
Jia X; Pan L; Zhu M; Hu H; Zhai L; Liu J; Hu M; Liu B; Tan M
J Proteomics; 2020 Jan; 210():103545. PubMed ID: 31626998
[TBL] [Abstract][Full Text] [Related]
12. Cereblon Promotes the Ubiquitination and Proteasomal Degradation of Interleukin Enhancer-Binding Factor 2.
Lian Q; Gao Y; Li Q; He X; Jiang X; Pu Z; Xu G
Protein J; 2020 Oct; 39(5):411-421. PubMed ID: 33009960
[TBL] [Abstract][Full Text] [Related]
13. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
[TBL] [Abstract][Full Text] [Related]
14. A critical evaluation of the approaches to targeted protein degradation for drug discovery.
Chopra R; Sadok A; Collins I
Drug Discov Today Technol; 2019 Apr; 31():5-13. PubMed ID: 31200859
[TBL] [Abstract][Full Text] [Related]
15. CUL4-DDB1-CRBN E3 Ubiquitin Ligase Regulates Proteostasis of ClC-2 Chloride Channels: Implication for Aldosteronism and Leukodystrophy.
Fu SJ; Hu MC; Peng YJ; Fang HY; Hsiao CT; Chen TY; Jeng CJ; Tang CY
Cells; 2020 May; 9(6):. PubMed ID: 32466489
[TBL] [Abstract][Full Text] [Related]
16. TRIP12 promotes small-molecule-induced degradation through K29/K48-branched ubiquitin chains.
Kaiho-Soma A; Akizuki Y; Igarashi K; Endo A; Shoda T; Kawase Y; Demizu Y; Naito M; Saeki Y; Tanaka K; Ohtake F
Mol Cell; 2021 Apr; 81(7):1411-1424.e7. PubMed ID: 33567268
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
18. The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Heider M; Eichner R; Stroh J; Morath V; Kuisl A; Zecha J; Lawatscheck J; Baek K; Garz AK; Rudelius M; Deuschle FC; Keller U; Lemeer S; Verbeek M; Götze KS; Skerra A; Weber WA; Buchner J; Schulman BA; Kuster B; Fernández-Sáiz V; Bassermann F
Mol Cell; 2021 Mar; 81(6):1170-1186.e10. PubMed ID: 33571422
[TBL] [Abstract][Full Text] [Related]
19. The CB
Costas-Insua C; Hermoso-López A; Moreno E; Montero-Fernández C; Álvaro-Blázquez A; Maroto IB; Sánchez-Ruiz A; Diez-Alarcia R; Blázquez C; Morales P; Canela EI; Casadó V; Urigüen L; Perea G; Bellocchio L; Rodríguez-Crespo I; Guzmán M
EMBO Mol Med; 2024 Apr; 16(4):755-783. PubMed ID: 38514794
[TBL] [Abstract][Full Text] [Related]
20. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
